Findings

What do systematic reviews say?

18 questions · 18 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 27.8%GRADE not reported 0 · 0%Very low 3 · 16.7%Low 5 · 27.8%Moderate 5 · 27.8%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Levomepromazine vs Typical antipsychotics · Leaving the study early ‐ short term ‐ any reason
  Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
  RR 1.11 [0.45, 2.74]
  1 study · 41 participants
  Low
Direct match · question page
- Levomepromazine vs Typical antipsychotics · Leaving the study early ‐ medium term ‐ any reason
  Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
  RR 2 [0.2, 19.62]
  1 study · 28 participants
  Very low
Direct match · question page
- Levomepromazine vs Typical antipsychotics · Leaving the study early ‐ long term ‐ any reason
  Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
  RR 0.4 [0.09, 1.81]
  1 study · 38 participants
  Moderate
Direct match · question page
- Levomepromazine vs Typical antipsychotics · Leaving the study early ‐ short term ‐ due to lack of efficacy
  Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
  RR 0.95 [0.22, 4.18]
  1 study · 41 participants
  Low
Direct match · question page
- Levomepromazine vs Atypical antipsychotics · Leaving the study early ‐ short term ‐ due to patient deterioration
  Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
  RR 5 [0.25, 98.27]
  1 study · 42 participants
  Moderate

Levomepromazine vs Typical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1.11 [0.45, 2.74]
1 study · 41 participants
Low

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.83 [0.4, 1.74]
2 studies · 106 participants
Very low

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ due to patient deterioration · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 5 [0.25, 98.27]
1 study · 42 participants
Moderate

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.74]
1 study · 42 participants
Low

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.95 [0.22, 4.18]
1 study · 41 participants
Low

Levomepromazine vs Typical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 4.77 [0.24, 93.67]
1 study · 41 participants
Low

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 2 [0.2, 19.62]
1 study · 28 participants
Very low

Levomepromazine vs Typical antipsychotics

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 0.4 [0.09, 1.81]
1 study · 38 participants
Moderate

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.07, 14.85]
1 study · 38 participants
Moderate

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.07, 14.85]
1 study · 38 participants
Moderate

Levomepromazine vs atypical antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 1 [0.67, 1.49]
2 studies · 106 participants
Low

Levomepromazine vs atypical antipsychotics

Withdrawals due to adverse events · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine for schizophrenia 2010 · Cochrane Headline outcomes only
RR 5 [0.25, 98.27]
1 study · 42 participants
Moderate

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation

It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no overall improvement compared with COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE (very low certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 8.18 [0.5, 133.66]
1 study · 19 participants
Very low

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Economic outcomes ‐ not measured · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE

Repeated need for tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found